OrbiMed Advisors Discloses 14.0% Stake in ADARx Pharmaceuticals

OrbiMed Advisors LLC has disclosed a 14.0% stake in ADARx Pharmaceuticals, Inc.'s common stock. The Schedule 13D filing, made on October 2, 2026, follows ADARx's September 28 IPO, which included OrbiMed-led purchases and preferred stock conversions.